Abstract:Lung cancer is amongst the most common types of cancer throughout the world. The overall 5-year survival rate is similar to 17%. A number of studies have demonstrated that the microbiome existing within the host may affect the level of inflammation, and consequently contribute to the carcinogenesis of certain types of cancer. To investigate the role of inflammation and the microbiome in the carcinogenesis of lung cancer, an intervention study involving mice, including a control group (C; n = 5), a urethane-induced pulmonary adenocarcinoma group (U; n = 5) and a prebiotics intervention group (P; n = 5) was carried out. This pulmonary adenocarcinoma model was reviewed, and incidences of the disease were identified using histopathology. The levels of the inflammatory cytokines nuclear factor kappa B (NF-kappa B), tumor necrosis factor alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and IL-6 in the sera samples were measured using an ELISA technique. In addition, high-throughput sequencing of the 16S ribosomal RNA gene segment was used to analyze the species present in the microbiome of the lower airways and intestinal tracts of mice. The results demonstrated that groups P and U exhibited altered histopathology and the development of lung adenocarcinoma tumors, but no differences were observed between the groups. The level of inflammation, determined by measuring the levels of NF-kappa B, TNF-alpha, IL-1 beta and IL-6 inflammatory cytokines, was significantly lower in group P compared with group U (P < 0.05), and was significantly higher in group P compared with group C (P < 0.05). Overall, the microbiomes of the lower respiratory and intestinal tracts did not change markedly among the 3 groups, in terms of the size of colonies and Shannon diversity indices. However, at a family and operational taxonomic unit (OTU) level, certain microbiota were altered. For example, the abundance of the Clostridiales and Lachnospiraceae families was lower in the lung and intestinal tracts subsequent to urethane-induced treatment compared with in the control group (P < 0.05), and the level of abundance of the Clostridiales family increased to similar levels within the control group (P < 0.05), when prebiotics were administered. The levels of abundance of the S24-7, Bacteroidales and Firmicutes families were higher in the intestinal tract compared with the control group (P < 0.05), and following treatment with prebiotics, the levels of abundance of these families decreased to similar levels observed in the control group (P < 0.05). In conclusion, inflammation and the microbiome serve important roles in the carcinogenesis of lung cancer. Additionally, prebiotics may increase the efficacy of lung cancer treatment by modulating levels of inflammation and the composition of the microbiome. The associations between inflammation, the microbiome and lung cancer require attention.

Impact of Pulmonary microbiota on lung cancer treatment-related pneumonia

Impact of Radiotherapy Concurrent with Anti-PD-1 Therapy on the Lung Tissue of Tumor-Bearing Mice.

The Safety and Efficacy of Immunotherapy with Anti-Programmed Cell Death 1 Monoclonal Antibody for Lung Cancer Complicated with Mycobacterium Tuberculosis Infection

Role of Respiratory System Microbiota in Development of Lung Cancer and Clinical Application

The Function and Molecular Mechanism of Commensal Microbiome in Promoting Malignant Progression of Lung Cancer

Prospective Correlation Between the Patient Microbiome with Response to and Development of Immune-Mediated Adverse Effects to Immunotherapy in Lung Cancer.

Microbiome Related Cytotoxically Active CD8+ TIL Are Inversely Associated With Lung Cancer Development

Gut microbiome affects the response to immunotherapy in non-small cell lung cancer

Alleviating lung injury and pulmonary fibrosis in radiotherapy-immunotherapy combination: The role of low-dose radiation therapy.

The impact of chronic obstructive pulmonary disease on the risk of immune-related pneumonitis in lung cancer patients undergoing immunotherapy: a systematic review and meta-analysis

Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study

Special tissue microbiota such as Cyanobacteria are associated with the immune microenvironment of lung adenocarcinoma

The gut microbiota modulates responses to anti-PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors

The Human Microbiome: A Promising Target for Lung Cancer Treatment

Unveiling the Immunophenotypes of Pneumonitis in Cancer Treatment Through Mass Cytometry Exploration

The Association Between Inflammation, the Microbiome and Urethane-Induced Pulmonary Adenocarcinoma

Impact on hospitalization and infection patterns of advanced lung cancer with lower respiratory tract infections: Targeted therapy vs. chemoradiotherapy

Implications of intestinal microecology and immune function alterations for immunotherapy outcomes in advanced unresectable lung adenocarcinoma

Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer

The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy

Gut microbiota and association with clinical response to anti-PD-1 based immunotherapy combined with chemotherapy in Chinese patients with lung cancer.